← Leaderboards
Michael Davies
University Of Tx Md Anderson Can Ctr
$11,575,720
Attributed
$14,424,094
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,979,404 · 12
By mechanism
U54$13,964,025 · 4
P50$11,206,154 · 5
T32$5,219,481 · 1
R01$3,589,744 · 2
Top collaborators
- Meenhard Herlyn13 shared
- Patrick Hwu7 shared
- Katy Rezvani3 shared
- Jessie Villanueva3 shared
- Richard E. Champlin2 shared
- Courtney Dinardo2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Rehan Akbani$4,444,254
- Ronald Anthony Depinho$97,148,322
- Ganesh Rao$4,692,231
- Y. Alan Wang$3,748,710
- Chun Li$8,657,872
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMelanomaMolecularTumorMalignant NeoplasmsMetastatic MelanomaPathway InteractionsResponseResistancePre-Clinical ModelCombinatorialMutantBraf GeneMutationTargeted TreatmentResourcesCutaneous MelanomaResistance MechanismFutureIn VivoResearch Clinical TestingMelanoma CellInhibitor/AntagonistPrevent
Grant awards (58)
Rational Approaches to Melanoma Therapy$1,284,372
U54 · FY2025 · CA
Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma$333,518
U54 · FY2025 · CA · contact PI
Rational Approaches to Melanoma Therapy$1,220,153
U54 · FY2024 · CA
Research Training in Academic Medical Oncology$649,322
T32 · FY2024 · CA · contact PI
Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma$378,415
U54 · FY2024 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Melanoma$2,070,386
P50 · FY2023 · CA · contact PI
Rational Approaches to Melanoma Therapy$635,508
U54 · FY2023 · CA
Research Training in Academic Medical Oncology$602,683
T32 · FY2023 · CA · contact PI
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN$479,648
P50 · FY2023 · CA · contact PI
Administrative Core 1$282,967
P50 · FY2023 · CA · contact PI
Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma$130,262
U54 · FY2023 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Melanoma$2,058,691
P50 · FY2022 · CA · contact PI
Research Training in Academic Medical Oncology$591,629
T32 · FY2022 · CA · contact PI
Rational approaches to melanoma therapy$589,729
U54 · FY2022 · CA
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN$415,046
P50 · FY2022 · CA · contact PI
Administrative Core 1$244,858
P50 · FY2022 · CA · contact PI
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$129,712
U54 · FY2022 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Melanoma$1,943,851
P50 · FY2021 · CA · contact PI
Rational approaches to melanoma therapy$1,391,843
U54 · FY2021 · CA
Research Training in Academic Medical Oncology$563,952
T32 · FY2021 · CA · contact PI
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN$387,285
P50 · FY2021 · CA · contact PI
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$308,002
U54 · FY2021 · CA · contact PI
Rational approaches to melanoma therapy (PDXNet Administrative Supplement to R01CA121118)$120,000
U54 · FY2021 · CA
Rational approaches to melanoma therapy (PDXNet Administrative Supplement to R01CA241148)$120,000
U54 · FY2021 · CA
The University of Texas MD Anderson Cancer Center SPORE in Melanoma$2,127,987
P50 · FY2020 · CA · contact PI
Rational approaches to melanoma therapy$1,400,393
U54 · FY2020 · CA
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN$531,105
P50 · FY2020 · CA · contact PI
Research Training in Academic Medical Oncology$362,121
T32 · FY2020 · CA · contact PI
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$308,002
U54 · FY2020 · CA · contact PI
Administrative Core 1$249,285
P50 · FY2020 · CA · contact PI
Rational approaches to melanoma therapy$1,430,873
U54 · FY2019 · CA
Research Training in Academic Medical Oncology$522,717
T32 · FY2019 · CA · contact PI
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN$415,045
P50 · FY2019 · CA · contact PI
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$330,502
U54 · FY2019 · CA · contact PI
Rational approaches to melanoma therapy$119,969
U54 · FY2019 · CA
Rational approaches to melanoma therapy$119,969
U54 · FY2019 · CA
Rational approaches to melanoma therapy$36,000
U54 · FY2019 · CA
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$19,994
U54 · FY2019 · CA · contact PI
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$19,994
U54 · FY2019 · CA · contact PI
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$6,001
U54 · FY2019 · CA · contact PI
Research Training in Academic Medical Oncology$509,745
T32 · FY2018 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2018 · CA
The role of the PI3K pathway in immune resistance$160,000
R01 · FY2018 · CA
Rational approaches to melanoma therapy$2,885,586
U54 · FY2017 · CA
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery$645,228
U54 · FY2017 · CA · contact PI
Research Training in Academic Medical Oncology$470,270
T32 · FY2017 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2017 · CA
The role of the PI3K pathway in immune resistance$160,000
R01 · FY2017 · CA
Research Training in Academic Medical Oncology$490,275
T32 · FY2016 · CA
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2016 · CA
Research Training in Academic Medical Oncology$456,767
T32 · FY2015 · CA
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2015 · CA
The Role of the PI3K-AKT Pathway in Melanoma Brain Metastasis$327,850
R01 · FY2015 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2014 · CA
The Role of the PI3K-AKT Pathway in Melanoma Brain Metastasis$318,015
R01 · FY2014 · CA · contact PI
The Role of the PI3K-AKT Pathway in Melanoma Brain Metastasis$308,179
R01 · FY2013 · CA · contact PI
The Role of the PI3K-AKT Pathway in Melanoma Brain Metastasis$327,850
R01 · FY2012 · CA · contact PI
The Role of the PI3K-AKT Pathway in Melanoma Brain Metastasis$327,850
R01 · FY2011 · CA · contact PI